Article
Immunology
Constantina Boikos, Lauren Fischer, Dan O'Brien, Joe Vasey, Gregg C. Sylvester, James A. Mansi
Summary: The study compared the effectiveness of different vaccines in preventing influenza-related medical encounters in adults aged 65 and older. Results showed that aIIV3 demonstrated greater reduction in influenza-related medical encounters compared to IIV4 and HD-IIV3 in both 2017-2018 and 2018-2019 US influenza seasons.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Pablo Manuel Bianculli, Lucile Bellier, Ignacio Olivera Mangado, Carlos Grau Perez, Gustavo Mieres, Luis Lazarov, Audrey Petitjean, Hugo Dibarboure, Juan Guillermo Lopez
Summary: This study evaluated the cost-utility of replacing trivalent influenza vaccine with quadrivalent influenza vaccine in Uruguay. The results showed that using quadrivalent influenza vaccine could avoid a considerable number of influenza cases and healthcare consultations, and save workdays. It is cost-effective, especially for the target populations in Uruguay, particularly for older adults.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Yaping Chen, Yanhui Xiao, Ying Ye, Feng Jiang, Hanqing He, Linyun Luo, Haiping Chen, Lubin Shi, Qiuyue Mu, Wei Chen, Xue Guo, Min Zhang, Jun Li, Qinghu Guan, Zhiping Chen, Xiaoming Yang
Summary: This study demonstrates that in infants, coadministration of an inactivated enterovirus 71 vaccine (EV71 vaccine) with trivalent split-virion inactivated influenza vaccine (IIV3) is safe and does not interfere with immunogenicity.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Mark Loeb, Margaret L. Russell, Caralyn Kelly-Stradiotto, Nola Fuller, Kevin Fonseca, David J. D. Earn, Khami Chokani, Lorne Babiuk, Binod Neupane, Pardeep Singh, Eleanor Pullenayegum
Summary: The study found that vaccinating children with MF59 adjuvanted trivalent influenza vaccine did not significantly reduce influenza infection rates in children and family members compared to inactivated quadrivalent vaccine, but it did result in significant protection against influenza A in children.
Article
Biotechnology & Applied Microbiology
Xiaoqiang Liu, Juliana Park, Shengli Xia, Bin Liang, Shuangmin Yang, Yanxia Wang, Olga Syrkina, Nathalie Lavis, Shuzhen Liu, Chenyan Zhao, Jian Ding, Jieqiong Hu, Sandrine Samson, Iris A. de Bruijn
Summary: The safety and immunogenicity of the quadrivalent, split-virion influenza vaccine (Shz QIV) developed in China were assessed. The vaccine showed good tolerability and induced immune responses in different age groups, demonstrating non-inferiority against various strains of influenza virus.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Biotechnology & Applied Microbiology
Antonio Arbo, Celia Martinez-Cellular, Cynthia Vazquez, Lucile Bellier, Cecilia Adorno, Hugo Dibarboure, Juan Guillermo Lopez, Audrey Petitjean, Pablo Bianculli
Summary: This study investigates the public health and economic benefits of using a quadrivalent influenza vaccine (QIV) instead of a trivalent influenza vaccine (TIV) in past seasons in Paraguay. The findings suggest that switching from TIV to QIV could have prevented influenza cases, hospitalizations, and deaths, potentially generating savings for the health system and society. The impact is influenced by vaccine prices and coverage rate.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Manjusha Gaglani, Anupama Vasudevan, Chandni Raiyani, Kempapura Murthy, Wencong Chen, Michael Reis, Edward A. Belongia, Huong Q. McLean, Michael L. Jackson, Lisa A. Jackson, Richard K. Zimmerman, Mary Patricia Nowalk, Arnold S. Monto, Emily T. Martin, Jessie R. Chung, Sarah Spencer, Alicia M. Fry, Brendan Flannery
Summary: The study compared the vaccine effectiveness of quadrivalent and trivalent influenza vaccines against illness due to influenza B during the transition in the United States. Results showed that quadrivalent vaccines were more effective against influenza B cases, especially for the B lineage not included in the trivalent vaccines.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Sarah Spencer, Jessie R. Chung, Edward A. Belongia, Maria Sundaram, Jennifer Meece, Laura A. Coleman, Richard K. Zimmerman, Mary Patricia Nowalk, Krissy Moehling Geffel, Ted Ross, Chalise E. Carter, David Shay, Min Levine, Justine Liepkalns, Jin Hyang Kim, Suryaprakash Sambhara, Mark G. Thompson, Brendan Flannery
Summary: Individuals with type 2 diabetes mellitus and those without showed similar serologic responses to the trivalent influenza vaccine, with greater fold-increases in antibody titer occurring among those with lower pre-vaccination antibody titers. The waning of antibody titers was not influenced by diabetes status.
INFLUENZA AND OTHER RESPIRATORY VIRUSES
(2022)
Article
Immunology
Constantina Boikos, Lauren Fischer, Dan O'Brien, Joe Vasey, Gregg C. Sylvester, James A. Mansi
Summary: This study estimated the relative vaccine effectiveness (rVE) of cell-propagated inactivated quadrivalent influenza vaccine (ccIIV4) versus egg-derived inactivated quadrivalent influenza vaccine (eIIV4) in preventing influenza-related medical encounters in the 2018-2019 US season. The results showed a statistically significantly greater reduction in influenza-related medical encounters in individuals vaccinated with ccIIV4 compared to eIIV4, supporting ccIIV4 as a potentially more effective public health measure against influenza.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Ahmed Tawfik, Takahisa Kawaguchi, Meiko Takahashi, Kazuya Setoh, Izumi Yamaguchi, Yasuharu Tabara, Kristel Van Steen, Anavaj Sakuntabhai, Fumihiko Matsuda
Summary: This study investigated the immunogenicity of influenza vaccine in two independent groups. The results showed that a single dose of the vaccine provided equal protection after three months for both annually vaccinated adults and first-time vaccine receivers.
EXPERT REVIEW OF VACCINES
(2023)
Article
Immunology
Mbayame Nd Niang, Jonathan D. Sugimoto, Aldiouma Diallo, Bou Diarra, Justin R. Ortiz, Kristen D. C. Lewis, Kathryn E. Lafond, M. Elizabeth Halloran, Marc-Alain Widdowson, Kathleen M. Neuzil, John C. Victor
Summary: This study in Senegal found variable effectiveness of the trivalent inactivated influenza vaccine against influenza illness in children, with total and indirect vaccine effectiveness present when all circulating strains matched the vaccine formulation.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Huakun Lv, Xuejiao Pan, Hui Liang, Ying Wang, Yu Hu
Summary: Reports to the national adverse event following immunization surveillance system (NAEFISS) following inactivated quadrivalent influenza vaccine (QIV) in Zhejiang province from 2018 to 2020 did not reveal any new or unexpected safety concerns. Continual monitoring of the safety of QIV is recommended.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Immunology
Diana Tavares, Helena Mourino, Cristina Anton Rodriguez, Carlos Martin Saborido
Summary: This study evaluates the cost effectiveness of switching from trivalent inactivated vaccine (TIV) to quadrivalent inactivated vaccine (QIV) in the Portuguese elderly population from the perspective of the National Health Service. The findings indicate that QIV is not cost effective due to its high cost.
Article
Virology
Artur Capao, Maria L. Aguiar-Oliveira, Braulia C. Caetano, Thayssa K. Neves, Paola C. Resende, Walquiria A. F. Almeida, Milene D. Miranda, Olindo A. ssis Martins-Filho, David Brown, Marilda M. Siqueira, Cristiana C. Garcia
Summary: Annual vaccination against influenza is crucial in preventing deaths and hospitalizations. The effectiveness of trivalent inactivated influenza vaccines (TIV) is influenced by antigenic mismatches, age, previous immunity, and other host factors. A study on Brazilian volunteers revealed that TIV significantly enhanced antibody titers and seroprotection, but the response weakened over time. Regular evaluations based on regional influenza strain circulation and the factors affecting vaccine response are recommended.
Article
Immunology
Lucile Bellier, Audrey Petitjean, Tatiana Sarazu, Julio Tresierra, Juan Guillermo Lopez
Summary: The study evaluated the cost-effectiveness of switching from trivalent to quadrivalent influenza vaccines in Peru, showing that introducing QIV instead of TIV is expected to be a cost-effective strategy, especially for younger children and the elderly. The benefits of QIV would be even greater if the coverage targeted by the Ministry of Health is reached, leading to significant health and economic impact in preventing influenza infections.
Article
Medicine, General & Internal
Alexander Shivarev, Anastasia Phillips, Sam Brophy-Williams, Tim Ford, Peter Richmond, Paul Effler, Andrew McLean-Tooke
Summary: Within the first 4 months of the Western Australian COVID-19 immunisation programme, there were 49 reported cases of suspected anaphylaxis in the vaccine safety surveillance system. Out of these, 12 cases met the Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Pediatrics
Katie Attwell, Lara McKenzie, Sian Tomkinson, Samantha J. Carlson, Christopher C. Blyth
Summary: In August 2022, Australian authorities began offering COVID-19 vaccines to children under 5 years old with serious comorbidities. This study examines parents' vaccine intentions to inform current and future vaccine roll-outs for young children. Two thirds of parents intended to vaccinate, while one third planned to delay due to various concerns.
JOURNAL OF PAEDIATRICS AND CHILD HEALTH
(2023)
Editorial Material
Medicine, General & Internal
Maddie Heenan, Lucie Rychetnik, Elly Howse, Paul J. Beggs, Tarun S. Weeramanthri, Fiona Armstrong, Ying Zhang
MEDICAL JOURNAL OF AUSTRALIA
(2023)
Article
Medicine, Research & Experimental
C. McLeod, J. Ramsay, K. L. Flanagan, M. Plebanski, H. Marshall, M. Dymock, J. Marsh, M. J. Estcourt, U. Wadia, P. C. M. Williams, M. C. Tjiam, C. Blyth, K. Subbarao, S. Nicholson, S. Faust, R. B. Thornton, A. Mckenzie, T. L. Snelling, P. Richmond
Summary: PICOBOO is a flexible platform trial designed to assess the effectiveness of different COVID-19 vaccination strategies in Australia. The modular and hierarchical protocol structure aims to standardize research processes and minimize duplication, allowing for agility in responding to new research questions.
Article
Immunology
Thomas Benfield, Mika Ramet, Piero Valentini, Ilkka Seppa, Ron Dagan, Peter Richmond, Swati Mercer, Clay Churchill, Robert Lupinacci, Richard McFetridge, Jun Park, Frederick Wittke, Natalie Banniettis, Luwy Musey, Kara Bickham, Janusz Kaminski
Summary: This phase III study evaluated the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants. Results showed that V114 demonstrated non-inferior immune responses to 13 shared serotypes and superior immune responses to additional serotypes 22F and 33F, compared with PCV13. The two-dose primary series plus toddler dose of V114 was well-tolerated in healthy infants.
Article
Immunology
Federico Martinon-Torres, Jacek Wysocki, Leszek Szenborn, Alfonso Carmona-Martinez, Airi Poder, Ron Dagan, Peter Richmond, Christopher Gilbert, Marie-Chantale Trudel, Sheryl Flores, Robert Lupinacci, Richard McFetridge, Richard T. Wiedmann, Qiuxu Chen, Han Gerrits, Natalie Banniettis, Luwy Musey, Kara Bickham, Janusz Kaminski
Summary: This study evaluated the safety and immunogenicity of V114 and PCV13 in healthy infants. The results showed that V114 elicited immune responses to 13 shared serotypes comparable to PCV13, and had superior responses to two additional serotypes. These findings support the routine use of V114 in infants.
Article
Obstetrics & Gynecology
Lisa McHugh, Annette K. Regan, Mohinder Sarna, Hannah C. Moore, Paul Van Buynder, Gavin Pereira, Christopher C. Blyth, Karin Lust, Ross M. Andrews, Kristy Crooks, Peter Massey, Michael J. Binks
Summary: Compared to other Australian women, First Nations women are less likely to receive recommended antenatal vaccines, while women from culturally and linguistically diverse backgrounds are more likely to receive them. Women living in remote areas are less likely to be vaccinated, while women living in areas of advantage are more likely to be vaccinated. Addressing these disparities should be a core priority for the Australian healthcare system and vaccine providers.
BMC PREGNANCY AND CHILDBIRTH
(2023)
Article
Biochemical Research Methods
Yue C. Wu, Steven Mascaro, Mejbah Bhuiyan, Parveen A. Fathima, Ariel Mace, Mark L. Nicol, Peter Richmond, Lea-Ann Kirkham, Michael A. Dymock, David L. Foley, Charlie C. McLeod, Meredith E. Borland, Andrew V. Martin, Phoebe C. M. E. Williams, Julie V. Marsh, Thomas E. Snelling, Christopher E. Blyth
Summary: This study developed a causal Bayesian network model to predict the causative pathogen for pediatric pneumonia. The model demonstrated reliable diagnostic performance and aid in antibiotic treatment decisions. This research provides a novel approach to addressing the challenges in diagnosing and treating pneumonia.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Pediatrics
Jane Tuckerman, Kelly Harper, Thomas R. R. Sullivan, Alana R. R. Cuthbert, Jennifer Fereday, Jennifer Couper, Nicholas Smith, Andrew Tai, Andrew Kelly, Richard Couper, Mark Friswell, Louise Flood, Christopher C. C. Blyth, Margie Danchin, Helen S. S. Marshall
Summary: This study aimed to assess the effectiveness of Flutext-4U, a parent SMS reminder intervention, in increasing influenza vaccination in children and adolescents with special risk medical conditions. The results suggest that providing additional SMS reminders to parents in a tertiary care hospital setting can improve influenza vaccine uptake.
Article
Multidisciplinary Sciences
Gladymar Perez Chacon, Parveen Fathima, Mark Jones, Marie J. Estcourt, Heather F. Gidding, Hannah C. Moore, Peter C. Richmond, Tom Snelling
Summary: A retrospective cohort study found no clinically relevant association between early infant vaccination with whole-cell pertussis (wP) vaccine and hospital presentations for asthma in childhood.
Article
Medicine, Research & Experimental
Prabha H. H. Andraweera, Bing Wang, Margie Danchin, Christopher Blyth, Ivo Vlaev, Jason Ong, Jodie Dodd, Jennifer Couper, Thomas R. R. Sullivan, Jonathan Karnon, Nicola Spurrier, Michael Cusack, Dylan Mordaunt, Dimi Simatos, Gus Dekker, Samantha Carlson, Jane Tuckerman, Nicholas Wood, Lisa Whop, Helen S. S. Marshall
Summary: This study aims to assess the effectiveness of a multi-component nudge intervention to improve influenza and COVID-19 vaccine uptake among pregnant women. The intervention includes SMS text message reminders and educational videos to increase vaccination rates. The results of this study will provide guidance for future vaccination efforts among pregnant women.
Article
Immunology
Mohinder Sarna, Amanuel Gebremedhin, Peter Richmond, Avram Levy, Kathryn Glass, Hannah C. Moore
Summary: Respiratory syncytial virus is a major cause of illness and death in infants worldwide. By analyzing pre-pandemic RSV testing data and hospital admission data, a statistical prediction model was used to estimate RSV-hospitalizations in infants under 1 year old. The highest incidence rate of RSV-hospitalization in infants under 6 months was found in those born in April/May.
Article
Immunology
Huong Le, Nicholas de Klerk, Christopher C. Blyth, Heather Gidding, Parveen Fathima, Hannah C. Moore
Summary: This study assesses the causal impact of seasonal influenza vaccine on respiratory syncytial virus (RSV) hospitalizations in children using an instrumental variable strategy. The results show that influenza vaccine reduces the risk of RSV hospitalizations, especially in children under 2 years old.
Article
Immunology
Christopher C. Blyth, Parveen Fathima, Rebecca Pavlos, Peter Jacoby, Olivia Pavy, Elizabeth Geelhoed, Peter C. Richmond, Paul Effler, Hannah C. Moore
Summary: The study found that increasing childhood influenza vaccine coverage can significantly reduce influenza cases and healthcare costs. For children under 5 years old, every 10% increase in vaccine coverage saves over AU$1.5 million in costs. Including primary-school aged children in the vaccination program results in additional benefits, with every 10% increase in coverage reducing cases, presentations, hospitalisations, and saving approximately AU$4 million in net costs.
